# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

C. Measurand: Oxycodone

D. Type of Test: Homogenous enzyme immunoassay

E. Applicant: Immunalysis Corporation

F. Proprietary and Established Names: Immunalysis Oxycodone Urine Enzyme Immunoassay Immunalysis Oxycodone Urine Calibrators Immunalysis Oxycodone Urine Controls

# G. Regulatory Information:

1. Regulation section: 21 CFR $\$ 862.3650$ Opiate Test System 21 CFR $\$ 862.3200$ Clinical Toxicology Calibrator 21 CFR $\ S$ 862.3280 Clinical Toxicology Control Material

2. Classification: Class II for 862.3650 and 862.3200 Class I, reserved for 862.3280

3. Product code: DJG Enzyme Immunoassay, Opiates DLJ Calibrators, Drug Specific LAS Drug Specific Control Materials

4. Panel: Toxicology (91)

# H. Intended Use:

1. Intended use(s): The Immunalysis Oxycodone Urine Enzyme Immunoassay is a homogenous enzyme immunoassay with a dual cutoff of $1 0 0 ~ \mathrm { { n g / m L } }$ and $3 0 0 ~ \mathrm { { n g / m L } }$ . The assay is intended for use in laboratories for the qualitative and semi-quantitative analysis of Oxycodone in human urine with automated clinical chemistry analyzers. This assay is calibrated against Oxycodone. This in-vitro diagnostic device is for prescription use only. The semi-quantitative mode is for purposes of enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GC-MS or permitting laboratories to establish quality control procedures.

The Immunalysis Oxycodone Urine Enzyme Immunoassay Kit provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrometry (GC-MS) or Liquid Chromatography/Mass Spectroscopy (LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used.

The Immunalysis Oxycodone Urine Calibrators are used as calibrators in the Immunalysis Oxycodone Urine Enzyme Immunoassay for the qualitative and semi-quantitative determination of Oxycodone in urine on automated clinical chemistry analyzers.

The Immunalysis Oxycodone Urine Controls are used as control materials in the Immunalysis Oxycodone Urine Enzyme Immunoassay.

2. Indication(s) for use: See intended uses above.

3. Special conditions for use statement(s):

For prescription use only · For in vitro diagnostic use only

4. Special instrument requirements:

The Beckman Coulter AU400e Chemistry Analyzer was used to generate the performance data in this submission.

# I. Device Description:

The assay consists of antibody/substrate reagent and enzyme conjugate reagent. The antibody/substrate reagent includes recombinant monoclonal antibodies to Oxycodone, glucose-6-phosphate (G6P) and nicotinamide adenine dinucleotide (NAD) in Tris buffer with Sodium Azide as a preservative. The enzyme conjugate reagent includes oxycodone derivative labeled with glucose-6-phosphate dehydrogenase (G6PDH) in Tris buffer with Sodium Azide as a preservative.

Calibrators and control materials are prepared from synthetic negative urine and a commercially available oxycodone drug standard. The concentration of the Oxycodone in these calibrators and control materials is determined by Liquid

chromatography/Mass Spectroscopy (LC/MS).

The following calibrators are available:

Oxycodone Calibrator Set (0, $1 0 0 \mathrm { n g / m L }$ , $3 0 0 ~ \mathrm { { n g / m L } }$ , $5 0 0 \mathrm { n g / m L }$ and $1 0 0 0 \mathrm { n g / m L ) }$ for the semi-quantitative mode. $1 0 0 ~ \mathrm { { n g / m L } }$ Oxycodone Calibrator for the $1 0 0 \mathrm { n g / m L }$ cutoff $3 0 0 ~ \mathrm { { n g / m L } }$ Oxycodone Calibrator for the $3 0 0 \mathrm { n g / m L }$ cutoff

The following control materials are available:

· Oxycodone Controls set for the $1 0 0 \mathrm { n g / m L }$ cutoff $( 7 5 \mathrm { n g / m L }$ and $1 2 5 \mathrm { n g / m L }$ ) Oxycodone Control set for the $3 0 0 \mathrm { n g / m L }$ cutoff $( 2 2 5 \mathrm { n g / m L }$ and $3 7 5 \mathrm { n g / m L } )$

Oxycodone Calibrators and controls are sold separately. Reagents are liquid, ready to use.

# J. Substantial Equivalence Information:

1. Predicate device name(s): DRI Oxycodone Assay, DRI Oxycodone Calibrators and DRI Oxycodone Controls

2. Predicate K number(s): k040411

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Immunalysis OxycodoneUrine Enzyme Immunoassay</td><td rowspan=1 colspan=1>Predicatek040411</td></tr><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the qualitative and semi-quantitative analysis ofOxycodone in human urine atcutoffs of 100 and 300 ng/mL</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Measured Analyte</td><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Test Matrix</td><td rowspan=1 colspan=1>Human urine</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Cutoff Level</td><td rowspan=1 colspan=1>100 ng/mL and 300 ng/mL</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Technology</td><td rowspan=1 colspan=1>Homogenous enzymeimmunoassay</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Antibodies</td><td rowspan=1 colspan=1>Recombinant FAB antibody tooxycodone</td><td rowspan=1 colspan=1>Mouse monoclonalanti-oxycodonederivative</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Immunalysis Oxycodone UrineCalibrators</td><td colspan="1" rowspan="1">Predicatek040411</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For the calibration of the theImmunalysis Oxycodone Urine</td><td colspan="1" rowspan="1">For the calibrationof the DRI</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Enzyme Immunoassay</td><td colspan="1" rowspan="1">Oxycodone Assay</td></tr><tr><td colspan="1" rowspan="1">Calibrator Form</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">same</td></tr><tr><td colspan="1" rowspan="1">Calibrator Levels</td><td colspan="1" rowspan="1">Five levels (0, 100, 300, 500 and1000 ng/mL)</td><td colspan="1" rowspan="1">same</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Immunalysis OxycodoneUrine Controls</td><td rowspan=1 colspan=1>Predicatek040411</td></tr><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Intended as control materials forthe Immunalysis OxycodoneUrine Enzyme Immunoassay</td><td rowspan=1 colspan=1>Intended as controlmaterials for theDRI OxycodoneAssay</td></tr><tr><td rowspan=1 colspan=1>Control Levels</td><td rowspan=1 colspan=1>2 Levels (75 and 125 ng/mL or225 and 375 ng/mL)</td><td rowspan=1 colspan=1>same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Evaluation of Precision Performance of Quantitative Measurement Methods:   
Approved Guideline (EP5-A2)   
Interference Testing in Clinical Chemistry; Approved Guideline (EP7-A2)   
Draft Guidance for Industry and FDA Staff Premarket Submission and Labeling   
Recommendations for Drugs of Abuse Screening Tests

# L. Test Principle:

The assay uses an Oxycodone specific antibody. The assay is based on the competition of Oxycodone labeled enzyme glucose-6-phosphate dehydrogenase (G6PDH) and the free drug in the urine sample for the fixed amount of antibody binding sites. In the absence of the free drug in the sample, the antibody binds the drug enzyme conjugate and enzyme activity is inhibited. This creates a dose response relationship between drug concentration in the urine sample and enzyme activity. The enzyme G6PDH activity is determined at $3 4 0 \mathrm { n m }$ spectrophotometrically by the conversion of NAD to NADH.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The sponsor performed precision studies in-house following the guidelines provided in CLSI EP5-A2. The study was performed using drug free urine spiked with Oxycodone and 1 reagent lot using 1 Beckman Coulter AU400e Chemistry Analyzer. Samples were measured in duplicate on 2 runs per day for 20 days $\scriptstyle ( \ n = 8 0 )$ ). The data are summarized in the following table:

Qualitative analysis (100ng/mL cutoff)   

<table><tr><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>% ofcutoff</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>46 negative34 positive</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>80positive</td></tr><tr><td rowspan=1 colspan=1>175</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>80positive</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>80 positive</td></tr></table>

Qualitative analysis $( 3 0 0 \mathrm { n g / m L }$ cutoff)   

<table><tr><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>% ofcutoff</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>35 negative45 positive</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>80 positive</td></tr></table>

Semi-Quantitative analysis $\mathrm { { ( 1 0 0 n g / m L } }$ cutoff)   

<table><tr><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>% ofcutoff</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>57 negative23 positive</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>175</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>80 positive</td></tr></table>

Semi-Quantitative analysis $( 3 0 0 \mathrm { n g / m L }$ cutoff)   

<table><tr><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>% ofcutoff</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-100%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>-75%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>-50%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>-25%</td><td rowspan=1 colspan=1>80 negative</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>38 negative42 positive</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>+25%</td><td rowspan=1 colspan=1>80 positive</td></tr><tr><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>+50%</td><td rowspan=1 colspan=1>80positive</td></tr><tr><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>+75%</td><td rowspan=1 colspan=1>80positive</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>+100%</td><td rowspan=1 colspan=1>80 positive</td></tr></table>

# $b$ . Linearity/assay reportable range:

A drug free urine pool was spiked with a high concentration of Oxycodone and was used as the high value specimen. Additional pools were made by serially diluting the high value specimen with drug free urine in increments of $10 \%$ . Aliquots from each pool were analyzed in duplicate in the semiquantitative mode using all 6 calibrators for the $1 0 0 ~ \mathrm { { n g / m L } }$ and $3 0 0 ~ \mathrm { { n g / m L } }$ cutoffs (0, 100, 300, 500, $1 0 0 0 ~ \mathrm { { n g / m L } }$ ) using 2 Beckman Coulter AU400e Chemistry Analyzers. For each known concentration, drug recovery was calculated using the mean concentration of the replicates. Summary results are listed below:

<table><tr><td rowspan=1 colspan=1>ExpectedConcentration(ng/mL)</td><td rowspan=1 colspan=1>Mean MeasuredConcentration(ng/mL)</td><td rowspan=1 colspan=1>Recovery(%)</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>27.4</td><td rowspan=1 colspan=1>110</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50.2</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100.4</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>228.1</td><td rowspan=1 colspan=1>114</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>307.3</td><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>443.8</td><td rowspan=1 colspan=1>111</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>514.1</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>606.6</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>732.9</td><td rowspan=1 colspan=1>105</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>787.1</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>900</td><td rowspan=1 colspan=1>870.9</td><td rowspan=1 colspan=1>104</td></tr><tr><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>937</td><td rowspan=1 colspan=1>94</td></tr><tr><td rowspan=1 colspan=1>1100</td><td rowspan=1 colspan=1>969.8</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>1200</td><td rowspan=1 colspan=1>1001.4</td><td rowspan=1 colspan=1>83</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods): The controls and calibrators are prepared using a commercially available Oxycodone standard. The concentration of Oxycodone in these calibrators and controls is determined by LC/MS analysis.

Stability: Protocols and acceptance criteria were reviewed and found to be acceptable. The sponsor claims that when stored at $2 { - } 8 ~ ^ { \circ } \mathrm { C }$ calibrators and controls are stable for 10 months.

The sponsor claims that once opened, the calibrators and controls are stable for 14 days if stored on-board the instrument at ambient temperature (22 to $2 8 ^ { \circ } \mathrm { C } )$ ).

d. Detection limit: Not applicable e. Analytical specificity:

Interference studies:

Structurally non-similar compounds and endogenous compound were evaluated to ensure that there was no interference that caused a false response relative to the cutoff in the qualitative mode and semi-quantitative mode. Results were analyzed following the recommendations in CLSI EP 7-A2. Potential interfering and endogenous substances were spiked into drug free urine containing Oxycodone $1 1 \pm 2 5 \%$ of the cutoff $7 5 \mathrm { { n g / m L } }$ and $1 2 5 \mathrm { n g / m L }$ for the $1 0 0 \mathrm { n g / m L }$ cutoff and $2 2 5 \mathrm { n g / m L }$ and $3 7 5 \mathrm { n g / m L }$ for the $3 0 0 \mathrm { n g / m L }$ cutoff). Each sample was tested in replicates of 4 for the qualitative testing and in duplicate for the semi-quantitative testing using 2 Beckman Coulter AU400e Chemistry Analyzers and compared to the corresponding Oxycodone control.

The following structurally non-similar compounds (each tested at 100,000 $\mathrm { n g / m L ) }$ were found not to interfere with the test result at either cutoff in both qualitative and semi-quantitative modes:

Acetaminophen, Alprazolam, d-Amphetamine, Amitryptyline, Amobarbital, Benzoylecgonine, Bromazepam, Caffeine, Clonazepam, Carbamazine, Carisoprodol, Chlorpromazine, Desipramine, Dextromethorphan, Diazepam, Diphenhydramine, Doxepine, Doxylamine, Flunitrazepam, Flurazepam, Fluoxetine, Ibuprofen, Imipramine, Ketamine, Lidocaine, LSD, Lorazepam, 3,4-MDA, 3,4-MDEA, 3,4-MDMA, PMA, Medazepam, Methadone Metabolite (EDDP), Methaqualone, d-Methamphetamine, Meprobamate, Mephenytoin, Methylphenidate, Methadone, Naproxen, Nordiazepine, Nortriptyline, Oxazepam, Phenobarbital, Phencyclidine (PCP), Pentobarbital, Phenothiazine, Propoxyphene, Pentazocine, Protriptyline, Salicylic acid,

Secobarbital, Sertraline, Pseudo-ephedrine, Ranitidine, Temazepam, 11-norcarboxy- $\cdot \Delta 9$ -THC, Tramadol, Triazolam, Zolpidem

The following endogenous substances at the tested concentrations did not interfere with the results of the assay at either cutoff:

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration Tested</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>1.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>0.002 g/dL</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>0.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>γ-Globulin</td><td rowspan=1 colspan=1>0.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>2.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>0.300 g/dL</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin</td><td rowspan=1 colspan=1>0.5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Oxalic Acid</td><td rowspan=1 colspan=1>0.1 g/dL</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>0.0075 g/dL</td></tr><tr><td rowspan=1 colspan=1>Sodium Azide</td><td rowspan=1 colspan=1>1% w/v</td></tr><tr><td rowspan=1 colspan=1>SodiumChloride</td><td rowspan=1 colspan=1>6.0 g/dL</td></tr><tr><td rowspan=1 colspan=1>SodiumFluoride</td><td rowspan=1 colspan=1>1% w/v</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>6.0 g/dL</td></tr></table>

Boric acid at $1 \% \mathrm { w / v }$ resulted in a false negative results at both cutoffs. The sponsor included the following limitation in the labeling:

“Boric acid at $1 \% \mathrm { ~ w ~ } / \mathrm { v }$ resulted in false negative results at both cutoffs. Boric Acid is not recommended as a preservative for urine.”

Effect of pH: The sponsor evaluated the effect of $\mathsf { p H }$ on the test results using both qualitative and semi-quantitative modes. Drug free urine containing Oxycodone a $. t \pm 2 5 \%$ of the cutoff $7 5 \mathrm { n g / m L }$ and $1 2 5 \mathrm { n g / m L }$ for the $1 0 0 \mathrm { n g / m L }$ cutoff and $2 2 5 \mathrm { n g / m L }$ and $3 7 5 \mathrm { n g / m L }$ for the $3 0 0 \mathrm { n g / m L }$ cutoff) were pH adjusted using hydrochloric acid or sodium hydroxide. pH values of 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 and 11.0 did not interfere with the test result at either cutoff.

Effect of specific gravity: The sponsor evaluated the effect of specific gravity on the test results using both qualitative and semi-quantitative modes. Drug free urine containing Oxycodone $a t \pm 2 5 \%$ of the cutoff $( 7 5 \mathrm { n g / m L }$ and $1 2 5 \mathrm { n g / m L }$ for the $1 0 0 \mathrm { n g / m L }$ cutoff and $2 2 5 \mathrm { n g / m L }$ and $3 7 5 \mathrm { n g / m L }$ for the $3 0 0 \mathrm { n g / m L }$ cutoff) were adjusted using salt/albumin. Specific Gravity values of 1.000, 1.002, 1.005, 1.010, 1,015, 1.020, 1.025 and 1.030 did not interfere with the test result at either cutoff.

Cross reactivity from structurally related compounds was evaluated in the qualitative and semi-quantitative modes. Oxycodone and the structurally similar compound (listed below) were spiked into drug free urine at levels that will trigger the $1 0 0 \mathrm { n g }$ and $3 0 0 \mathrm { n g / m L }$ Oxycodone cutoff. Each sample was tested in singlicate for the semi-quantitative mode and in replicates of 4 for the qualitative mode using 2 Beckman Coulter AU400e Chemistry Analyzers. The results are summarized below and are expressed as the minimum concentration of metabolite or compound required to produce a response approximately equivalent to each cutoff concentration of the assay. If no crossreactivity was observed, then the concentration in the table is the concentration tested and “N.D.” or none detected is reported.

$1 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>Concentration Tested(ng/mL)</td><td rowspan=1 colspan=1>Cross-Reactivity (%)</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Noroxymorphone</td><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>2.00</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone-3β-Glucuronide</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>20.00</td></tr><tr><td rowspan=1 colspan=1>Noroxycodone</td><td rowspan=1 colspan=1>7,500</td><td rowspan=1 colspan=1>1.33</td></tr><tr><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>3,750</td><td rowspan=1 colspan=1>2.67</td></tr><tr><td rowspan=1 colspan=1>Naloxone, 3-Glucuronide</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>0.20</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>30,000</td><td rowspan=1 colspan=1>0.33</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>350,000</td><td rowspan=1 colspan=1>&lt;0.10</td></tr><tr><td rowspan=1 colspan=1>Normorphine</td><td rowspan=1 colspan=1>1,000,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Dihydrocodeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Norcodeine</td><td rowspan=1 colspan=1>1,000,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Heroin</td><td rowspan=1 colspan=1>300,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Meperidine</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Levorphanol</td><td rowspan=1 colspan=1>200,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Buprenorphine</td><td rowspan=1 colspan=1>10,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>Morphine-3β-Glucuronide</td><td rowspan=1 colspan=1>500,000</td><td rowspan=1 colspan=1>N.D.</td></tr><tr><td rowspan=1 colspan=1>6-Acetyl Morphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>N.D.</td></tr></table>

$3 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td colspan="1" rowspan="1">Compound</td><td colspan="1" rowspan="1">Concentration Tested(ng/mL)</td><td colspan="1" rowspan="1">Cross-Reactivity (%)</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone</td><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="1">Noroxymorphone</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">0.60</td></tr><tr><td colspan="1" rowspan="1">Oxymorphone-3β-Glucuronide</td><td colspan="1" rowspan="1">4,000</td><td colspan="1" rowspan="1">7.50</td></tr><tr><td colspan="1" rowspan="1">Noroxycodone</td><td colspan="1" rowspan="1">75,000</td><td colspan="1" rowspan="1">0.40</td></tr><tr><td colspan="1" rowspan="1">Naloxone</td><td colspan="1" rowspan="1">37,500</td><td colspan="1" rowspan="1">0.80</td></tr><tr><td colspan="1" rowspan="1">Naloxone, 3-Glucuronide</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">&lt;0.10</td></tr><tr><td colspan="1" rowspan="1">Naltrexone</td><td colspan="1" rowspan="1">300,000</td><td colspan="1" rowspan="1">0.10</td></tr><tr><td colspan="1" rowspan="1">Morphine</td><td colspan="1" rowspan="1">350,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Normorphine</td><td colspan="1" rowspan="1">1,000,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Dihydrocodeine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Norcodeine</td><td colspan="1" rowspan="1">1,000,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Heroin</td><td colspan="1" rowspan="1">300,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Hydromorphone</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Meperidine</td><td colspan="1" rowspan="1">50,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">200,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Buprenorphine</td><td colspan="1" rowspan="1">10,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">Morphine-3β-Glucuronide</td><td colspan="1" rowspan="1">500,000</td><td colspan="1" rowspan="1">N.D.</td></tr><tr><td colspan="1" rowspan="1">6-Acetyl Morphine</td><td colspan="1" rowspan="1">100,000</td><td colspan="1" rowspan="1">N.D.</td></tr></table>

f. Assay cut-off:

Analytical performance of the device around the claimed cutoff is described in the precision section (1 a.) above.

2. Comparison studies:

a. Method comparison with predicate device:

The method comparison study was performed in-house using 169 unaltered, leftover clinical urine samples obtained from clinical testing laboratories and were analyzed using one lot of the proposed device using 2 Beckman Coulter AU400e Chemistry Analyzers. The sponsor compared the results of their device to results obtained using liquid chromatography/mass spectroscopy (LC/MS). The results of the assay performance compared to LC/MS are summarized below:

The following table summarizes the performance of the assay for the $1 0 0 \mathrm { n g / m L }$ cutoff:

$1 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=2 colspan=1>Candidate DeviceResult</td><td rowspan=1 colspan=5>OxycodoneConcentration (ng/mL)</td><td rowspan=2 colspan=1>Agreement(%)</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;50</td><td rowspan=1 colspan=1>50-99</td><td rowspan=1 colspan=1>100-150</td><td rowspan=1 colspan=1>&gt;150</td></tr><tr><td rowspan=1 colspan=1>Qualitative/POS</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Qualitative/NEG</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Semi-quant/POS</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Semi-quant/NEG</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

The following tables summarize the performance of the assay for the $3 0 0 \mathrm { n g / m L }$ cutoff:

$3 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=2 colspan=1>Candidate DeviceResult</td><td rowspan=1 colspan=5>Oxycodone Concentration (ng/mL)</td><td rowspan=2 colspan=1>Agreement(%)</td></tr><tr><td rowspan=1 colspan=1>NEG</td><td rowspan=1 colspan=1>&lt;150</td><td rowspan=1 colspan=1>150-299</td><td rowspan=1 colspan=1>300-450</td><td rowspan=1 colspan=1>&gt;450</td></tr><tr><td rowspan=1 colspan=1>Qualitative/POS</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>5**</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Qualitative/NEG</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>92</td></tr><tr><td rowspan=1 colspan=1>Semi-quant/POS</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>5**</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Semi-quant/NEG</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>92</td></tr></table>

Discordant samples at the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff   

<table><tr><td rowspan=1 colspan=4>Candidate Device Result</td><td rowspan=3 colspan=1>LC/MS Result(ng/mL)</td></tr><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Qualitative</td><td rowspan=1 colspan=2>Semi-Quantitative</td></tr><tr><td rowspan=1 colspan=1>Value</td><td rowspan=1 colspan=1>Result</td></tr><tr><td rowspan=1 colspan=1>10478*</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>479</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>Oxycodone at 60 andOxymorphone at 45</td></tr><tr><td rowspan=1 colspan=1>10203**</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>407</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>Oxycodone at 61 andOxymorphone at 91</td></tr><tr><td rowspan=1 colspan=1>10466*</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>431</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>Oxycodone at 100 andOxymorphone 38</td></tr><tr><td rowspan=1 colspan=1>10472**</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>841</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>Oxycodone at 157 andOxymorphone at 11</td></tr><tr><td rowspan=1 colspan=1>10477**</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>1409</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>Oxycodone at 173andOxymorphone at 75</td></tr><tr><td rowspan=1 colspan=1>10192**</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>603</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>Oxycodone at 180andOxymorphone at 8</td></tr><tr><td rowspan=1 colspan=1>10471**</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>553</td><td rowspan=1 colspan=1>POS</td><td rowspan=1 colspan=1>Oxycodone at 196 andOxymorphone at 60</td></tr></table>

\* The Sponsor investigated the cause of these false positive results and suspected sample integrity issues though this could not be verified. Therefore the Sponsor conducted testing of additional samples and the false results were not replicated in this study.

b. Matrix comparison: This device is intended for use on urine samples only.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.